Neumora Therapeutics Statistics
Total Valuation
NMRA has a market cap or net worth of $297.38 million. The enterprise value is $212.02 million.
| Market Cap | 297.38M |
| Enterprise Value | 212.02M |
Important Dates
The next estimated earnings date is Wednesday, August 5, 2026, after market close.
| Earnings Date | Aug 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NMRA has 185.28 million shares outstanding. The number of shares has increased by 4.83% in one year.
| Current Share Class | 185.28M |
| Shares Outstanding | 185.28M |
| Shares Change (YoY) | +4.83% |
| Shares Change (QoQ) | +6.74% |
| Owned by Insiders (%) | 4.46% |
| Owned by Institutions (%) | 38.02% |
| Float | 113.85M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.25 |
| P/TBV Ratio | 4.33 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.09, with a Debt / Equity ratio of 0.76.
| Current Ratio | 5.09 |
| Quick Ratio | 4.88 |
| Debt / Equity | 0.76 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -42.99 |
Financial Efficiency
Return on equity (ROE) is -148.74% and return on invested capital (ROIC) is -77.15%.
| Return on Equity (ROE) | -148.74% |
| Return on Assets (ROA) | -66.39% |
| Return on Invested Capital (ROIC) | -77.15% |
| Return on Capital Employed (ROCE) | -176.21% |
| Weighted Average Cost of Capital (WACC) | 17.71% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.42M |
| Employee Count | 92 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, NMRA has paid $55,000 in taxes.
| Income Tax | 55,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +58.82% in the last 52 weeks. The beta is 2.77, so NMRA's price volatility has been higher than the market average.
| Beta (5Y) | 2.77 |
| 52-Week Price Change | +58.82% |
| 50-Day Moving Average | 1.78 |
| 200-Day Moving Average | 2.19 |
| Relative Strength Index (RSI) | 48.06 |
| Average Volume (20 Days) | 4,392,382 |
Short Selling Information
The latest short interest is 4.92 million, so 2.65% of the outstanding shares have been sold short.
| Short Interest | 4.92M |
| Short Previous Month | 5.58M |
| Short % of Shares Out | 2.65% |
| Short % of Float | 4.32% |
| Short Ratio (days to cover) | 2.83 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -218.08M |
| Pretax Income | -222.34M |
| Net Income | -222.39M |
| EBITDA | -218.03M |
| EBIT | -218.08M |
| Earnings Per Share (EPS) | -$1.32 |
Balance Sheet
The company has $147.07 million in cash and $53.37 million in debt, with a net cash position of $93.70 million or $0.51 per share.
| Cash & Cash Equivalents | 147.07M |
| Total Debt | 53.37M |
| Net Cash | 93.70M |
| Net Cash Per Share | $0.51 |
| Equity (Book Value) | 70.68M |
| Book Value Per Share | 0.39 |
| Working Capital | 123.32M |
Cash Flow
| Operating Cash Flow | -193.40M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 59,000 |
| Net Borrowing | 57.16M |
| Free Cash Flow | -193.40M |
| FCF Per Share | -$1.04 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NMRA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.83% |
| Shareholder Yield | -4.83% |
| Earnings Yield | -72.74% |
| FCF Yield | -63.26% |
Analyst Forecast
The average price target for NMRA is $6.53, which is 306.85% higher than the current price. The consensus rating is "Buy".
| Price Target | $6.53 |
| Price Target Difference | 306.85% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |